2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Sarcopenia
1
Prediabetic State
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Neoplasms
1
Myelodysplastic Syndromes
1
Muscle Weakness
1
Leukemia, Myeloid
1
Hematologic Neoplasms
1
Heart Failure
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Cardiotoxicity
1
Breast Neoplasms
1
Anemia, Aplastic
1
Interventions
Doxorubicin
17
Echocardiography
14
Exercise
9
Cyclophosphamide
9
Trastuzumab
8
Dexrazoxane
8
Electrocardiography
7
Razoxane
6
Carvedilol
6
Vincristine
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Cisplatin
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiotoxicity
×
nicotinamide-beta-riboside
×
Clear all
NCT05732051
2023-03-17
NARNIA
University Hospital, Akershus
Phase 2
Recruiting
60 enrolled